Jacques Raphael retweeted
The role of gut microbiota as a potential biomarker for first-line treatment selection in NSCLC has remained unclear. This biomarker study from the Phase III NIPPON trial by Hakozaki et al. provides new insights into this topic.
Read now ➡️ bit.ly/451nKub
Jacques Raphael retweeted
Hady Habib does it! Two days ago Lebanon had never had a Grand Slam main draw participant, now they have a match winner!
And look at what it means!
He defeats Bu 7-6(4) 6-4 7-6(6)
@wwos • @espn • @eurosport • @wowowtennis • #AusOpen • #AO2025
Jacques Raphael retweeted
THE EDMONTON OILERS HAVE FORCED A #GAME7!!!! 🤩 #StanleyCup
Jacques Raphael retweeted
A study by @JackRaph et al. shows early mortality is common among patients with cancer treated with immunotherapy.
The study suggests the need for a predictive tool to improve patient selection for ICI treatment in routine clinical practice.
Read here:
doi.org/10.1093/jnci/djad090
Jacques Raphael retweeted
“A cancer patient. A cancer case. Common terms, but ones that can have a great impact on patients and their mental health.”
A new @TheLancetOncol Editorial discusses person-first language and treating patients with respect at every turn: hubs.li/Q024gWnc0
Jacques Raphael retweeted
#CAMO23 Congratulations👏 to Dr. Nupur Krishnan for Best Poster Presentation➡️Immune checkpoint inhibitors in the treatment of small cell lung cancer: A systematic review and meta-analysis @GillSharlene @camoprez @z_veitch
Jacques Raphael retweeted
ICES welcomes @JackRaph as a new scientist! Jacques' work includes conducting health services research, systematic reviews, and meta-analyses. Learn more about his research https://teapawt.net/t.co/cuWIl84XWP
Jacques Raphael retweeted
The European Organisation for Research and Treatment of Cancer (@EORTC) endorses #TargetTrial emulation with #RWD.
An organization with unmatched expertise in the design of #randomizedtrials embraces their explicit emulation when using observational data.
ejcancer.com/article/S0959-8…
Jacques Raphael retweeted
Important study. 1/5 pts over age 65 receiving std adj chemo received low relative dose intensity and had INFERIOR outcome. Reducing dose is not the first solution, choice of regimen, growth factors and supportive care are critical. @OncoAlert
Low-Intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE Trial ascopubs.org/doi/pdf/10.1200… @JCO_ASCO @ASCO @OncoAlert #breastcancer
Jacques Raphael retweeted
Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer | Journal of Clinical Oncology ascopubs.org/doi/abs/10.1200…
Jacques Raphael retweeted
Review of pathologic complete response (pCR) shows that evidence currently available does not support pCR used alone as a reliable surrogate endpoint in neoadjuvant randomized controlled trials for breast cancer. ja.ma/3En94dh #BCSM
Jacques Raphael retweeted
🎯Interesting study on pre-existing autoimmune disease in pts treated with anti-PD-1👏 @JNCI_Now
doi.org/10.1093/jnci/djac046
✅17 497 pts, retrosp.
✅Risk of mortality not ⬆️
✅some cases w favorable prognosis
👉underlying AD may not be a contraindication for IO
@myESMO @OncoAlert
Jacques Raphael retweeted
Jacques Raphael retweeted
Jacques Raphael retweeted
Another @RashdanAMD study with @lbarbera123 exploring effect of Radiotherapy with Cyclin-Dependent Kinase 4/6 Inhibitors: A Multi-institutional Safety and Toxicity Study redjournal.org/article/S0360… #bscm #radonc
Jacques Raphael retweeted
Immune-Related Toxic Effects and Treatment Outcomes in Patients With Cancer and Autoimmune Diseases Receiving Immune Checkpoint Inhibitor Therapy ascopost.com/news/july-2022/… #oncology #cancer #immunotherapy
Jacques Raphael retweeted
Are you an inspirational leader in #Oncology? Come join the Department of Oncology @SchulichMedDent @LHSCCanada in London, Ontario as our new Chair/Chief! We are a fantastic multidisciplinary and collaborative academic clinical department. Please RT
uwo.ca/facultyrelations/care…
Jacques Raphael retweeted
In this recent #ICESWestern study, @JackRaph et al found the use of #immunotherapy to treat advanced #cancers rose substantially in Ontario since its approval. https://teapawt.net/t.co/KZQ1hGVNB6 1/

































